

Oxurion NV Announces the Passing of Dr. Claude Sander, Chief Legal Officer and Corporate Secretary to the Board

Leuven, Belgium, 21 December 2019 – It is with profound sadness that the Board, Management and Staff of Oxurion NV (Euronext Brussels: OXUR) share the news that Chief Legal Officer and Corporate Secretary to the Board, Dr Claude Sander, passed suddenly on 20th December 2019.

Patrik De Haes, MD, CEO of Oxurion and Thomas Clay, Chairman of the Board of Oxurion comment:

“We are deeply shocked and extremely saddened with the passing of Claude. The thoughts of everyone at Oxurion are with his family and friends, and we would like to extend our deepest sympathies to them.”

“It was a privilege and pleasure to have known Claude and to have worked with him for almost a decade. Claude always demonstrated exceptional leadership in his role as Chief Legal Officer and more recently as Corporate Secretary to the Board, even in very challenging situations. He was both admired and respected for his relentless commitment, expertise and achievements. Claude made things work, not only for Oxurion as a business, but equally for all individual members of the Oxurion family. Claude will be deeply missed and will always have a very special place in our hearts.”

“On behalf of the Board, Management and all the staff at Oxurion, we would like to pay tribute to his contribution and long-lasting legacy to the Company.”

EN

For further information please contact:

| | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <u>Oxurion NV</u> Wouter Piepers, Global Head of Investor Relations & Corporate Communications Tel: +32 16 75 13 10 / +32 478 33 56 32 wouter.piepers@oxurion.com | <u>Citigate Dewe Rogerson</u> David Dible/ Sylvie Berrebi/Frazer Hall Tel: +44 20 7638 9571 oxurion@citigatedewerogerson.com |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing a pipeline of novel clinical drug candidates acting on VEGF-independent pathways for the treatment of diabetic eye disease, a leading cause of blindness in people of working age worldwide.

Oxurion's clinical pipeline comprises:

- THR-149, a plasma kallikrein inhibitor, that has shown positive topline Phase 1 results for the treatment of DME. The Company is currently preparing to conduct a Phase 2 clinical program, which is expected to start in H1 2020. THR-149 was developed in conjunction with Bicycle Therapeutics
- THR-687, a pan-RGD integrin inhibitor, that is in a Phase 1 clinical study assessing it as a treatment for DME. Results from this study are expected in early 2020. THR-687 is an optimized compound derived from a broader library of integrin inhibitors in-licensed from Galapagos.

Oxurion is headquartered in Leuven, Belgium, and is listed on the Euronext Brussels exchange under the symbol OXUR. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities law